MASH/MASLD incidence rates are continuing to rise globally year after year as the disease continues to be a global health concern. With one pharmaceutical drug now having received regulatory approval, there are also a number of therapeutics in late phase clinical trials; case studies of which will be discussed at the congress as well as pre-clinical developments. Potential alternatives for MASH diagnosis in the form of non-invasive biomarkers will be explored to replace the invasive liver biopsy. Advances in the research of MASH disease mechanisms such as genetic predisposition, gut microbiome and mitochondrial dysfunction will be covered as the disease pathology continues to be complex and not fully understood.

The 2025 meeting will be published later this year. If you would like to be a part of this exciting program contact Lauren Dennison –

To see last year’s program follow this link.

What our Delegates Say


"I liked the specific focus on NASH versus other meetings where NASH may only be a part of the overall meeting agenda."


"Great speakers, interactive sessions, well-organized and good combination of industry and academic attendees"


"It was a great meeting in several aspects – the organisation, the high quality of the presentations and discussions, and the networking. The two days were useful as well as enjoyable to meet colleagues and different stakeholders in the NASH field."

Speakers have included

Michael Charlton

Professor of Medicine, Chief of Hepatology and Medical Director, Transplantation Institute, University of Chicago Medicine

William Alazawi

Professor of Hepatology, Director of Research, Blizard Institute, Queen Mary University of London

Lopa Mishra

Merinoff Endowed Chair and Professor of Medicine, The Feinstein Institutes for Medical Research (Northwell Health) and Cold Spring Harbor Laboratory

Diana Julie Leeming

Director of Fibrosis, Hepatic and Pulmonary Research (HPR), Nordic Bioscience

Michelle T. Long

International Medical Vice President, NASH & Liver Diseases, Novo Nordisk, Denmark

Scott Harris

Chief Medical Officer, Altimmune, USA

Rebecca Taub

Chief Medical Officer, President of Research & Development, Madrigal Pharmaceuticals

Richard Torstenson

Director Global Regulatory Affairs, AstraZeneca

Load more

Past Sponsors

To become a business partner of the 2025 meeting contact Gavin Hambrook.
Email: Tel: +44(0) 7538368764.